Charles Schwab Investment Management Inc. Boosts Stock Position in Artivion, Inc. $AORT

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Artivion, Inc. by 5.0%, making it the owner of approximately 0.88% of the company, worth about $9.24 million.
• Insider selling activity includes SVP Marshall S. Stanton selling 26,132 shares for over $743,000, reducing their position by 24.81%.
• Artivion's stock received multiple upgrades from analysts, with target prices raised and an average rating of "Buy", reflecting positive expectations following a reported 15.3% increase in revenue compared to the prior year.

Charles Schwab Investment Management Inc. boosted its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 5.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 376,052 shares of the company's stock after acquiring an additional 17,860 shares during the period. Charles Schwab Investment Management Inc. owned 0.88% of Artivion worth $9,243,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AORT. Peregrine Capital Management LLC acquired a new position in Artivion in the first quarter valued at approximately $7,650,000. Point72 Asset Management L.P. acquired a new position in Artivion in the fourth quarter valued at approximately $5,573,000. First Trust Advisors LP acquired a new position in Artivion in the fourth quarter valued at approximately $4,771,000. Thornburg Investment Management Inc. acquired a new position in Artivion in the first quarter valued at approximately $3,261,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Artivion in the first quarter valued at approximately $3,162,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 12,500 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total transaction of $529,000.00. Following the sale, the chief executive officer owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the company's stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares in the company, valued at $2,826,084. This represents a 22.09% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 115,990 shares of company stock worth $4,435,823 over the last ninety days. Insiders own 8.10% of the company's stock.

Artivion Stock Up 0.1%

Shares of Artivion stock traded up $0.06 during trading hours on Friday, reaching $43.87. 342,981 shares of the company were exchanged, compared to its average volume of 630,482. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $45.07. The stock's fifty day moving average is $35.07 and its 200 day moving average is $29.31. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.07 billion, a PE ratio of -104.45 and a beta of 1.69.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. The business's quarterly revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JMP Securities upped their price objective on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Oppenheimer restated an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. LADENBURG THALM/SH SH cut Artivion from a "buy" rating to a "neutral" rating and upped their price target for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Finally, Canaccord Genuity Group upped their price target on Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Artivion presently has an average rating of "Buy" and a consensus price target of $40.63.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.